首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

2112610

胜肽合成市場（第三版）：依原料藥類型、胜肽合成方法類型、化學合成方法類型、營運規模、公司規模及地區分類－趨勢與預測至2035年

Peptide Synthesis Market (3rd Edition) by Type of API, Type of Peptide Synthesis Method, Type of Chemical Synthesis Method, Scale of Operation, Company Size, Geographical Regions - Trends and Forecast Till 2035

出版日期: 2026年08月17日 | 出版商:

Roots Analysis | 英文 390 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

胜肽合成市場概覽

全球胜肽合成市場預計將從今年的 44 億美元成長到 2035 年的 70 億美元，在整個預測期內實現 5.2% 的複合年成長率。

胜肽合成市場—成長與趨勢

肽類藥物因其代謝穩定性更高、生物標的特異性更強、結合親和性更高，相比小分子化合物，正成為備受關注的重要治療候選藥物。全球監管機構已批准近百種胜肽類療法用於治療癌症、慢性疼痛、糖尿病、感染疾病、多發性硬化症和骨質疏鬆症等慢性疾病。

胜肽類藥物研發管線的擴展，特別是用於治療糖尿病和肥胖症的GLP-1和GIP受體促效劑的增加，促使對原料藥原料藥生產的需求激增。然而，肽合成仍然是一個技術難度很高的過程，許多研發公司面臨產能長期短缺的問題。因此，一部分複雜的生產作業被外包給專業的胜肽藥物委託製造（CMO），這使得藥物研發公司能夠縮短產品上市時間並降低資本密集度。

為此，成熟的契約製造企業正在擴大其固相、液相和混合合成的生產能力，升級純化基礎設施，並實施自動化和人工智慧驅動的製程控制。包括CordenPharma、PolyPeptide和Cambrex在內的多家公司在過去一年中宣布了工廠擴建計劃，這反映出為填補下一代胜肽療法生產能力缺口而進行的大規模投資。

成長驅動力－支持市場擴張的因素

市場的主要促進因素之一是癌症、糖尿病和其他代謝紊亂等慢性疾病在全球範圍內的日益普及。這種不斷成長的治療需求推動了規模更大、更複雜的胜肽類藥物開發平臺的建立，促使製藥公司將原料藥（原料藥）的生產外包給專業的合約藥品生產組織（CDMO），以滿足臨床和商業供應需求。

胜肽合成技術的不斷進步，包括固相和液相合成方法的改進，以及混合合成法和微波輔助合成法的出現，正在提高合成效率、可擴展性和成本效益。這些創新使合約研發生產機構（CDMO）能夠承接結構更為複雜的專案。 CordenPharma與Viking Therapeutics簽訂的多年期契約，旨在支持GLP-1/GIP候選化合物VK2735的商業化生產，這充分體現了技術能力如何直接轉化為大規模的供應合約。

市場挑戰－阻礙進展的主要障礙

儘管需求強勁成長，市場仍面臨許多挑戰。胜肽類生產商和合約研發生產機構（CDMO）難以滿足對複雜、大批量胜肽類（尤其是GLP-1類似物）快速成長的需求，導致長期供應瓶頸。許多新一代胜肽類由於其更長的序列和額外的修飾，難以用傳統的固相或液相方法進行處理，需要對混合流或連續流平台進行大量資本投資，而這些平台目前仍處於商業性應用的早期階段。

此外，傳統的胜肽合成仍消耗大量的溶劑和資源，而朝向更環保、更永續的製程轉型則需要對製程進行重大重新設計，並增加額外成本。另外，生產能力仍然高度集中於特定地區，供應鏈容易受到區域性中斷和不斷變化的貿易政策的影響，包括影響美國藥品進口的關稅相關不確定性。

胜肽合成市場—關鍵洞察

本報告對肽合成市場的現狀進行了詳細分析，並指出了分銷合作夥伴、通路仲介業者和服務整合商的潛在成長機會。主要發現包括：

資本投資增加：CordenPharma 已投資超過 9 億歐元用於生產能力，PolyPeptide 已將其在馬爾默的生產能力提高了一倍，Cambrex 已將其在馬薩諸塞州沃爾瑟姆的工廠擴建，這反映出持續的資本投資，以填補全球肽類生產能力的缺口。
加速市場整合：Granules India 於 2025 年 4 月收購 Senn Chemicals，進入胜肽類 CDMO 領域，這清楚地表明了市場整合的持續趨勢，因為多元化的製藥和學名藥公司正在尋求透過有針對性的收購快速進入胜肽類生產領域。
合作夥伴關係與合作：近期達成的協議，例如 Hybio Pharmaceutical 與 iCarbonX Intelligent Peptide 的產品開發和生產協議，以及與 Sunshine Mandi Pharmaceutical 的減重Semaglutide注射劑的商業供應協議，顯示對大規模胜肽原料藥生產的依賴性日益增強。
綠色化學作為差異化因素：EUROAPI 和 StrainChem 在「永續液相肽合成」方面的合作，以及 Innovate UK 對永續GLP-1 生物製造的 913,659 歐元投資，表明對永續性的承諾正在成為 CDMO 選擇中的一個差異化因素。
未來關鍵機會：全球產能擴張速度仍無法滿足大規模生產胜肽類藥物（尤其是GLP-1類似物）的需求。新增產能投入運作的速度預計將成為決定CDMO競爭地位的關鍵因素，也是投資人密切關注的重要指標。

肽合成市場的細分

市場規模和機會分析是根據以下參數進行細分的：

按 API 類型

非專利API
新化學物質（NCE）

胜肽合成方法

化學合成
非化學合成

依化學合成方法類型

固相合成
液相合成
混合相合成

按營運規模

商業規模
臨床前/臨床規模

按公司規模

小規模企業
中型公司
大型企業和巨型企業

按地區

北美洲
美國
加拿大
歐洲
比利時
瑞士
英國
德國
愛爾蘭
荷蘭
義大利
法國
瑞典
其他歐洲國家
亞太地區及世界其他地區
中國
印度
日本
韓國
亞太地區其他國家

胜肽合成市場－主要細分市場

非專利原料藥領域正在推動胜肽合成市場的發展。

根據我們的市場評估，非專利原料藥預計將佔胜肽合成市場最大的佔有率。這一主導地位主要是由於第一代胜肽類藥物的專利到期以及品牌藥相對較高的成本，這些因素持續推動研發公司轉向生產非專利肽原料藥。

化學合成仍然佔最大佔有率。

從胜肽合成方法的類型來看，化學合成目前佔最大的市場佔有率。這種主導地位源自於化學合成的廣泛應用，因為它相比非化學方法具有許多優勢，例如可擴展性、柔軟性、成本效益和易於實施。

固相合成是胜肽合成的基礎。

在化學合成方法中，固相合成佔最大的市場佔有率。其主導地位源自於許多優勢，包括線性胜肽的快速生產、純化過程的簡化以及高成本效益。

同時，混合相合成領域預計在預測期內將以較高的複合年成長率成長。這一成長主要歸功於其對複雜長肽序列的適用性，而這類肽序列正擴大被納入開發平臺。透過結合固相和液相合成方法的優勢，混合合成能夠顯著提高效率、產率和成本效益，從而為難以以單一方法生產的新一代治療藥物帶來福音。

商業規模的生產製造佔了主導市場佔有率。

以營運規模計算，商業規模細分市場佔最大的市場佔有率，預計在預測期內將保持較高的複合年成長率。這主要是由於GMP級胜肽類原料藥生產涉及巨大的產量和高額的經濟價值。與臨床前和臨床規模項目相比，已上市治療藥物的長期商業供應合約產生的收入要高得多。

此外，胜肽類藥物一旦獲得監管部門批准，生產商通常會與製藥公司簽訂長期商業供應協議，從而確保未來數年穩定持續的收入來源。高純度合成胜肽的日益普及、大規模固相肽合成（SPPS）技術的進步以及合約研發生產機構（CDMO）產能的持續擴張，都進一步鞏固了這一領域。

歐洲在肽合成市場主導。

我們的市場預測顯示，歐洲預計將繼續佔全球肽合成市場收入的最大佔有率。這一主導地位源於該地區在全球生產能力方面的巨大佔有率、大量的臨床試驗以及建立在強大的產學研合作基礎上的穩健創新生態系統。

比利時在歐洲扮演著主導的角色，這得益於其作為主要生物技術中心的地位、政府對生命科學領域的大力支持以及在醫藥物流方面的戰略位置。瑞士也正在崛起成為一個重要的市場，這得益於其生命科學生態系統與巴赫姆製造地的深度融合。

亞太地區正在崛起成為成長最快的區域市場。

預計到2035年，亞太地區將達到最高的複合年成長率。這一可觀的成長得益於區域醫藥市場的不斷擴張、政府對生命科學領域的大量投資，以及低資本投入和充足熟練勞動力支撐的成本效益型生產生態系統。此外，藥明康德旗下子公司藥明新科（WuXi STA）等區域性製藥公司也進一步推動了這項成長。

肽合成市場主要公司範例

Amneal Pharmaceuticals
Asymchem
Aurisco Pharma
Dr Reddy's Laboratories
Hybio Pharmaceutical
JYMed Peptide
Neuland Labs
Sinopep-Allsino Biopharmaceutical
SK Pharmteco
WuXi STA（a WuXi AppTec company）

專家訪談與業界考察

本研究中提出的觀點和見解是基於與多位相關人員的討論。本研究報告包含與以下產業相關人員的詳細訪談記錄：

一家小規模德國公司的創始人和所有者
德國小規模企業財務總監
美國小型企業執行長
美國中小企業科學營運與技術行銷資深總監
愛爾蘭一家大型公司的胜肽類副總裁
日本某大型企業高階經理人、胜肽業務專案負責人
印度中小企業首席科學長兼聯合創辦人

本報告解答的主要問題

肽合成市場的主要參與者有哪些？
哪個地區是胜肽合成市場的主要驅動力？
肽合成市場的主要趨勢是什麼？
哪些因素可能會影響該市場的未來發展？
胜肽類原料契約製造企業面臨的主要挑戰是什麼？
目前和未來的市場規模是多少？
這個市場的複合年成長率是多少？
當前和未來的市場機會預計將在主要市場區隔領域中如何分佈？

章節概要
一家總部位於北美的胜肽合成公司
- AmbioPharm
- Creative Peptides
- CSBio
一家總部位於歐洲的胜肽合成公司
- Bachem
- BCN Peptides
- CordenPharma
- PolyPeptide
- Senn Chemicals
一家總部位於亞太地區的胜肽合成公司
- Auspep
- Hybio Pharmaceutical
- Peptide Institute
- ScinoPharm
肽合成領域的知名公司
- Amneal Pharmaceuticals
- Asymchem
- Aurisco Pharma
- Dr Reddy's Laboratories
- Hybio Pharmaceutical
- JYMed Peptide
- Neuland Labs
- Sinopep-Allsino Biopharmaceutical
- SK Pharmteco
- WuXi STA（a WuXi AppTec company）

第11章近期趨勢

章節概要
夥伴關係與合作
近期擴張
新型胜肽合成技術

第12章：臨床試驗分析

章節概要
研究範圍和調查方法
胜肽類藥物：臨床試驗分析

第13章區域能力分析

章節概要
關鍵假設和調查方法
胜肽合成和生產設施整體情況
北美胜肽合成能力
歐洲的胜肽合成能力
在亞太地區及世界其他地區具備胜肽合成能力。

第14章需求分析

章節概要
先決條件和調查方法
胜肽合成：全球年度需求

第15章：產能分析

章節概要
關鍵假設和調查方法
胜肽合成：全球設備產能
結論

第16章：潛在合作夥伴分析

第17章：製造與採購之間的決策架構

章節概要
前提條件和參數定義
關於內部生產或外部採購的決策架構。
結論

第18章胜肽類委託製造的總擁有成本

第19章：全球胜肽合成市場

第20章：胜肽合成市場（按原始藥物類型分類）

第21章：胜肽合成市場（依胜肽合成方法類型分類）

第22章：胜肽合成市場（依化學合成方法類型分類）

第23章：胜肽合成市場（依企業規模分類）

第24章：胜肽合成市場（依公司規模分類）

第25章：胜肽合成市場（按地區分類）

第26章市場機會分析：北美

第27章市場機會分析：歐洲

第28章市場機會分析：亞太及其他地區

第29章 SWOT分析

第30章：ROOT的策略建議

第31章來自初步調查的見解

第32章：報告結論

第33章：表格形式數據

第34章公司與組織列表

第35章客製化的機會

第36章 ROOT訂閱服務

第37章作者信息

簡介目錄圖表

Product Code: RA100326

PEPTIDE SYNTHESIS MARKET: OVERVIEW

As per Roots Analysis, the global peptide synthesis market is estimated to grow from USD 4.4 billion in the current year to USD 7.0 billion by 2035, registering a CAGR of 5.2% across the forecast period.

Peptide Synthesis Market: Growth and Trends

Peptides have emerged as an important class of therapeutic candidates, owing to their enhanced metabolic stability, biological target specificity and higher binding affinity compared to small molecules. Regulatory authorities across different regions of the world have approved close to 100 peptide therapeutics for the treatment of chronic diseases, including cancer, chronic pain, diabetes, HIV infection, multiple sclerosis, and osteoporosis.

The expanding pipeline of peptide-based drugs, particularly GLP-1 and GIP receptor agonists for diabetes and obesity, has translated into a sharp rise in demand for peptide API manufacturing. Peptide synthesis, however, remains a technically demanding process, and many developers face a persistent shortage of production capacity. As a result, an increasing share of complex manufacturing work is being outsourced to specialized peptide contract manufacturing organizations, enabling faster time to market and lower capital intensity for drug developers.

In response, established contract manufacturers are expanding solid phase, liquid phase, and hybrid synthesis capacity, upgrading purification infrastructure, and integrating automated and AI-assisted process controls. CordenPharma, PolyPeptide, Cambrex and several other players have announced facility expansions over the past year, reflecting the scale of investment being directed toward closing the manufacturing capacity gap for next-generation peptide therapeutics.

Growth Drivers: Factors Fueling Market Expansion

One of the significant drivers of the market is the rising global prevalence of chronic diseases such as cancer, diabetes and other metabolic disorders. This growing therapeutic need is fueling a larger and more complex peptide R&D pipeline, encouraging drug developers to outsource API production to specialized contract drug manufacturing organizations (CDMOs) for both clinical and commercial supply.

Continuous advancements in peptide synthesis technologies, including refinements to solid phase and liquid phase methods and the emergence of hybrid and microwave-assisted approaches, are improving efficiency, scalability and cost-effectiveness. These innovations are enabling CDMOs to take on more structurally complex projects. CordenPharma's multi-year agreement with Viking Therapeutics to support commercial manufacturing of the GLP-1 / GIP candidate VK2735 illustrates how technological capability is translating directly into large-scale supply commitments.

Market Challenges: Critical Barriers Hindering Progress

Despite strong growth in demand, the market faces several challenges. The manufacturing capacity of peptide producers and CDMOs is struggling to keep pace with the rapidly growing demand for complex, high-volume peptides, particularly GLP-1 analogs, resulting in persistent supply bottlenecks.. Many next-generation peptides involve longer sequences and additional modifications that strain conventional solid phase and liquid phase methods, requiring capital-intensive investment in hybrid and continuous flow platforms that are still gaining commercial adoption.

Additionally, traditional peptide synthesis remains solvent and resource intensive, and the shift toward greener, more sustainable processes requires meaningful process redesign and added cost. Manufacturing capacity also remains geographically concentrated, which leaves the supply chain exposed to regional disruptions and evolving trade policies, including tariff-related uncertainty affecting pharmaceutical imports into the US.

Peptide Synthesis Market: Key Insights

The report delves into the current state of the peptide synthesis market and identifies potential growth opportunities for distribution partners, channel intermediaries, and service integrators. Some key findings include:

Increasing Capital Investment: More than EUR 900 million was committed by CordenPharma in capacity investment, alongside PolyPeptide's capacity-doubling expansion in Malmo and Cambrex's facility expansion in Waltham, Massachusetts, reflecting sustained capital deployment toward closing the global peptide manufacturing capacity gap.
Accelerating Market Consolidation: Granules India's acquisition of Senn Chemicals in April 2025 to enter the peptide CDMO space is representative of continued consolidation, as diversified pharmaceutical and generics players seek rapid entry into peptide manufacturing through targeted acquisitions.
Partnership and Collaboration: Recent agreements, including Hybio Pharmaceutical's product development and manufacturing agreement with iCarbonX Intelligent Peptide and its commercial supply agreement with Sunshine Mandi Pharmaceutical for a semaglutide weight-loss injection, point to growing reliance on outsourced, large-scale peptide API production.
Green Chemistry as a Differentiator: EUROAPI's collaboration with StrainChem for Sustainable Liquid Phase Peptide Synthesis and Innovate UK's EUR 913,659 investment in sustainable GLP-1 biomanufacturing indicate that sustainability credentials are becoming a differentiating factor in CDMO selection.
Key Future Opportunities: Global capacity build-out continues to trail demand for high-volume peptides, particularly GLP-1 analogs. The pace at which new capacity comes online is expected to be a key determinant of competitive positioning among CDMOs, making it an important metric for investors to monitor.

Peptide Synthesis Market Segments

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of API

Generic APIs
New Chemical Entities

By Type of Peptide Synthesis Method

Chemical Synthesis
Non-Chemical Synthesis

By Type of Chemical Synthesis Method

Solid Phase Synthesis
Liquid Phase Synthesis
Hybrid Phase Synthesis

By Scale of Operation

Commercial Scale
Preclinical / Clinical Scale

By Company Size

Small Companies
Mid-sized Companies
Large and Very Large Companies

By Geographical Regions

North America
US
Canada
Europe
Belgium
Switzerland
UK
Germany
Ireland
Netherlands
Italy
France
Sweden
Rest of Europe
Asia-Pacific and Rest of the World
China
India
Japan
Korea
Rest of Asia-Pacific and Other Countries

Peptide Synthesis Market: Key Segments

Generic APIs Segment Leads the Peptide Synthesis Market

Based on our market assessment, the generic APIs segment is expected to account for the largest share of the peptide synthesis market. This leadership is primarily driven by patent expirations of first-generation peptide drugs and the comparatively high cost associated with branded therapies, which continues to push developers toward generic peptide API manufacturing.

Chemical Synthesis Method Retains Dominant Share

On the basis of type of peptide synthesis method, the chemical synthesis segment currently holds the largest market share. This dominance is attributed to the widespread adoption of chemical synthesis, driven by its scalability, flexibility, cost-effectiveness, and ease of implementation relative to non-chemical approaches.

Solid Phase Synthesis to be the Cornerstone of Peptide Synthesis

Within chemical synthesis methods, the solid phase synthesis segment holds the highest share of the market. This dominance stems from its numerous advantages, including rapid production of linear peptides, simplified purification, and cost-effectiveness.

The hybrid phase synthesis segment, on the other hand, is likely to grow at a higher CAGR during the forecast period. This growth is primarily attributed to its suitability for the complex and long peptide sequences entering the R&D pipeline. By combining the strengths of solid phase and liquid phase methods, hybrid synthesis offers improved efficiency, yield and cost-effectiveness for next-generation therapeutics that are difficult to manufacture using a single method alone.

Commercial Scale Manufacturing to Retain Dominant Share

Based on scale of operation, the commercial scale segment accounts for the largest market share and this segment will also register higher CAGR during the forecast period. This is mainly attributed to the substantial volumes and high monetary value associated with manufacturing GMP-grade peptide APIs. Long-term commercial supply agreements for marketed therapies generate revenue that significantly surpasses preclinical and clinical scale projects.

Moreover, once a peptide drug receives regulatory approval, manufacturers typically enter into long-term commercial supply agreements with pharmaceutical companies, ensuring stable and recurring revenue streams over several years. The increasing adoption of high-purity synthetic peptides, advancements in large-scale solid-phase peptide synthesis (SPPS) technologies, and continued expansion of manufacturing capacities by CDMOs further strengthen this segment.

Europe Dominates the Market for Peptide Synthesis

According to our market projections, Europe is expected to retain the highest share of global peptide synthesis market revenue. This dominance is attributable to the region's significant share of global manufacturing capacity, a higher number of clinical trials, and a robust innovation ecosystem built on strong academic-industry collaborations.

Belgium is a leading contributor within Europe, supported by its status as a major biotech hub, government incentives for the life sciences, and its strategic location for pharmaceutical logistics. Switzerland is also emerging as a key market, anchored by Bachem's manufacturing footprint and a deeply integrated life sciences ecosystem.

Asia-Pacific Emerges as the Fastest-Growing Regional Market

Asia-Pacific is expected to register the highest CAGR through 2035. This lucrative growth is driven by an expanding regional pharmaceutical market, significant government investment in life sciences, and a cost-effective manufacturing ecosystem supported by lower capital expenditure and skilled labor availability. This growth is being reinforced by regional manufacturers such as WuXi STA, a WuXi AppTec company.

Example Players in Peptide Synthesis Market

Amneal Pharmaceuticals
Asymchem
Aurisco Pharma
Dr Reddy's Laboratories
Hybio Pharmaceutical
JYMed Peptide
Neuland Labs
Sinopep-Allsino Biopharmaceutical
SK Pharmteco
WuXi STA (a WuXi AppTec company)

Expert Interview and Industry Insights

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Founder and Owner, Small Company, Germany
Chief Financial Officer, Small Company, Germany
Chief Business Officer, Small Company, US
Senior Director of Scientific Affairs and Technical Marketing, Small Company, US
Vice President, Peptides, Large Company, Ireland
Senior Manager, Peptide Business Project Leader, Large Company, Japan
Chief Scientific Officer, Co-Founder, Small Company, India

PEPTIDE SYNTHESIS MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the peptide synthesis market, focusing on key market segments, including type of API, type of peptide synthesis method, type of chemical synthesis method, scale of operation, company size and geographical regions.
Peptide Synthesis Market Landscape: A detailed assessment of the overall market landscape, featuring information on parameters such as year of establishment, company size, location of headquarters, type of product and API manufactured, scale of operation, type of service offered, synthesis method used, and regulatory certifications held by peptide API contract manufacturers.
Company Competitiveness Analysis: A benchmarking of peptide API contract manufacturers headquartered in North America, Europe, and Asia-Pacific and Rest of the World, based on relevant competitiveness parameters.
Company Profiles: In-depth profiles of prominent players engaged in offering peptide API contract manufacturing services, featuring information on their company overview, financial information (where available), service portfolio, manufacturing facilities and capabilities, and recent developments.
Recent Developments: A detailed analysis of recent partnerships and collaborations, facility expansions, and emerging peptide synthesis technologies, including chemo-enzymatic synthesis, continuous flow technology and green chemistry.
Clinical Trial Analysis: An analysis of ongoing and completed clinical trials related to peptide therapeutics, based on parameters such as trial phase, trial status, study design, therapeutic area, sponsor type and geography.
Regional Capability Analysis: An assessment of the regional distribution of peptide API contract manufacturing facilities and capabilities across North America, Europe, and Asia-Pacific and Rest of the World.
Demand Analysis: An estimate of the annual global demand for peptide API contract manufacturing, segmented by clinical and commercial demand, phase of development, mechanism of action, synthesis method and geography.
Capacity Analysis: An analysis of the global installed peptide API contract manufacturing capacity, distributed by company size, scale of operation, synthesis method and geography.
Likely Partners Analysis: An analysis identifying potential strategic partners for peptide API contract manufacturers across North America, Europe, and Asia-Pacific and Rest of the World.
Make versus Buy Decision Making Framework: A framework to help stakeholders evaluate the decision to develop in-house peptide manufacturing capabilities versus outsourcing to a contract manufacturer, across multiple illustrative scenarios.
Total Cost of Ownership: An analysis of the total cost of ownership for a peptide API contract manufacturing organization over a twenty-year horizon, distributed by capital and operational expenditure.
SWOT Analysis: A qualitative analysis of the strengths, weaknesses, opportunities and threats affecting stakeholders in the peptide synthesis market.

Key Questions Answered in this Report

Which are the leading companies in the peptide synthesis market?
Which region dominates the peptide synthesis market?
What are the key trends observed in the peptide synthesis market?
What factors are likely to influence the evolution of this market?
What are the primary challenges faced by peptide API contract manufacturers?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
The report helps in identifying customer demand by understanding the needs, preferences and behavior of the target audience in order to tailor products or services effectively.
The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

Complementary PPT Insights Pack
Complementary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Value and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product (GDP)
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross-Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
- 5.2.1. Recent Developments
- 5.2.2. Clinical Trial Analysis
- 5.2.3. Demand and Capacity Analysis
- 5.2.4. Total Cost of Ownership
5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

6.1. Chapter Overview
6.2. Overview of Peptides
- 6.2.1. Structural Analysis of Peptides
- 6.2.2. Classification of Peptides
- 6.2.3. Peptide Synthesis
- 6.2.4. Emerging Technologies for Peptide Synthesis
- 6.2.5. Peptide Modification
  - 6.2.5.1. N-terminal Modifications
  - 6.2.5.2. Internal Modifications
  - 6.2.5.3. C-terminal Modifications
  - 6.2.5.4. Other Modifications
- 6.2.6. Peptide Purification
- 6.2.7. Peptide Purity Guidelines
6.3. Overview of Contract Manufacturing
- 6.3.1. Need for Outsourcing in the Peptide Manufacturing Industry
- 6.3.2. General Considerations for Selecting a CMO Partner
- 6.3.3. Advantages of Outsourcing Manufacturing Operations
- 6.3.4. Risks and Challenges Associated with Outsourcing of Peptide API Manufacturing
6.4. Future Perspectives

7. REGULATORY LANDSCAPE

7.1. Chapter Overview
7.2. Regulatory Scenario: North America
- 7.2.1. Scenario in the US
  - 7.2.1.1. Overview
  - 7.2.1.2. General Guidelines for Peptide Manufacturing
7.3. Regulatory Scenario: Europe
- 7.3.1. Scenario in Europe
  - 7.3.1.1. Overview
  - 7.3.1.2. General Guidelines
- 7.3.2. Scenario in the UK
  - 7.3.2.1. Overview
  - 7.3.2.2. General Guidelines for Peptide Manufacturing
7.4. Regulatory Scenario: Asia-Pacific
- 7.4.1. Overview
- 7.4.2. Scenario in Australia
  - 7.4.2.1. General Guidelines for Peptide Manufacturing
- 7.4.3. Scenario in China
  - 7.4.3.1. General Guidelines for Peptide Manufacturing
  - 7.4.3.2. Tax-related Modifications in Chinese Pharmaceutical Sector
- 7.4.4. Scenario in India
  - 7.4.4.1. General Guidelines for Peptide Manufacturing
  - 7.4.4.2. Tax-related Modifications in Indian Pharmaceutical Sector
- 7.4.5. Scenario in Japan
  - 7.4.5.1. General Guidelines for Peptide Manufacturing
- 7.4.6. Scenario in South Korea
  - 7.4.6.1. General Guidelines for Peptide Manufacturing
7.5. Challenges Associated with Peptide Manufacturing

8. MARKET LANDSCAPE

8.1. Chapter Overview
8.2. Peptide Synthesis: Overall Market Landscape
- 8.2.1. Analysis by Year of Establishment
- 8.2.2. Analysis by Year of Experience of Peptide Synthesis Companies
- 8.2.3. Analysis by Company Size
- 8.2.4. Analysis by Location of Headquarters
- 8.2.5. Analysis by Type of Product Manufactured
- 8.2.6. Analysis by Type of API Manufactured
- 8.2.7. Analysis by Scale of Operation
- 8.2.8. Analysis by Type of Service Offered
- 8.2.9. Analysis by Type of Peptide Synthesis Method Used
- 8.2.10. Analysis by Type of Peptide Modification Offered
- 8.2.11. Analysis by Type of Purification Technology Used
- 8.2.12. Analysis by Regulatory Certifications and Accreditations
- 8.2.13. Analysis by Geographical Presence
- 8.2.14. Analysis by Location of Peptide Synthesis Facilities
8.3. List of Custom Peptide Manufacturers

9. COMPANY COMPETITIVENSS ANALYSIS

9.1. Chapter Overview
9.2. Key Parameters
9.3. Methodology
9.4. Company Competitiveness Analysis
- 9.4.1. Peptide Synthesis Companies Headquartered in North America
- 9.4.2. Peptide Synthesis Companies Headquartered in Europe
- 9.4.3. Peptide Synthesis Companies Headquartered in Asia-Pacific and Rest of the World

10. COMPANY PROFILES: PEPTIDE SYNTHESIS COMPANIES

10.1. Chapter Overview
10.2. Peptide Synthesis Companies based in North America
- 10.2.1. AmbioPharm
  - 10.2.1.1. Company Overview
  - 10.2.1.2. Peptide Synthesis Service Portfolio
  - 10.2.1.3. Peptide Synthesis Facilities and Capabilities
  - 10.2.1.4. Recent Developments and Future Outlook
- 10.2.2. Creative Peptides
  - 10.2.2.1. Company Overview
  - 10.2.2.2. Peptide Synthesis Service Portfolio
  - 10.2.2.3. Peptide Synthesis Facilities and Capabilities
  - 10.2.2.4. Recent Developments and Future Outlook
- 10.2.3. CSBio
  - 10.2.3.1. Company Overview
  - 10.2.3.2. Peptide Synthesis Service Portfolio
  - 10.2.3.3. Peptide Synthesis Facilities and Capabilities
  - 10.2.3.4. Recent Developments and Future Outlook
10.3. Peptide Synthesis Companies based in Europe
- 10.3.1. Bachem
  - 10.3.1.1. Company Overview
  - 10.3.1.2. Financial Information
  - 10.3.1.3. Peptide Synthesis Service Portfolio
  - 10.3.1.4. Peptide Synthesis Facilities and Capabilities
  - 10.3.1.5. Recent Developments and Future Outlook
- 10.3.2. BCN Peptides
  - 10.3.2.1. Company Overview
  - 10.3.2.2. Peptide Synthesis Service Portfolio
  - 10.3.2.3. Peptide Synthesis Facilities and Capabilities
  - 10.3.2.4. Recent Development and Future Outlook
- 10.3.3. CordenPharma
  - 10.3.3.1. Company Overview
  - 10.3.3.2. Peptide Synthesis Service Portfolio
  - 10.3.3.3. Peptide Synthesis Facilities and Capabilities
  - 10.3.3.4. Recent Developments and Future Outlook
- 10.3.4. PolyPeptide
  - 10.3.4.1. Company Overview
  - 10.3.4.2. Financial Information
  - 10.3.4.3. Peptide Synthesis Service Portfolio
  - 10.3.4.4. Peptide Synthesis Facilities and Capabilities
  - 10.3.4.5. Recent Developments and Future Outlook
- 10.3.5. Senn Chemicals
  - 10.3.5.1. Company Overview
  - 10.3.5.2. Peptide Synthesis Service Portfolio
  - 10.3.5.3. Peptide Synthesis Facilities and Capabilities
  - 10.3.5.4. Recent Developments and Future Outlook
10.4. Peptide Synthesis Companies based in Asia-Pacific
- 10.4.1. Auspep
  - 10.4.1.1. Company Overview
  - 10.4.1.2. Peptide Synthesis Service Portfolio
  - 10.4.1.3. Peptide Synthesis Facilities and Capabilities
  - 10.4.1.4. Recent Developments and Future Outlook
- 10.4.2. Hybio Pharmaceutical
  - 10.4.2.1. Company Overview
  - 10.4.2.2. Peptide Synthesis Service Portfolio
  - 10.4.2.3. Peptide Synthesis Facilities and Capabilities
  - 10.4.2.4. Recent Developments and Future Outlook
- 10.4.3. Peptide Institute
  - 10.4.3.1. Company Overview
  - 10.4.3.2. Peptide Synthesis Service Portfolio
  - 10.4.3.3. Peptide Synthesis Facilities and Capabilities
  - 10.4.3.4. Recent Developments and Future Outlook
- 10.4.4. ScinoPharm
  - 10.4.4.1. Company Overview
  - 10.4.4.2. Financial Information
  - 10.4.4.3. Peptide Synthesis Service Portfolio
  - 10.4.4.4. Peptide Synthesis Facilities and Capabilities
  - 10.4.4.5. Recent Developments and Future Outlook
10.5. Company Deep Dive: Peptide Synthesis Companies
- 10.5.1. Amneal Pharmaceuticals
  - 10.5.1.1. Company Details
  - 10.5.1.2. Financial Details
  - 10.5.1.3. SWOT Analysis
  - 10.5.1.4. Strategic Framework
  - 10.5.1.5. Recent Developments and Future Outlook
- 10.5.2. Asymchem
  - 10.5.2.1. Company Details
  - 10.5.2.2. Peptide Synthesis Service Portfolio
  - 10.5.2.3. Peptide Synthesis Facilities
  - 10.5.2.4. Financial Details
  - 10.5.2.5. SWOT Analysis
  - 10.5.2.6. Strategic Framework
  - 10.5.2.7. Recent Developments and Future Outlook
- 10.5.3. Aurisco Pharma
  - 10.5.3.1. Company Details
  - 10.5.3.2. Peptide Synthesis Facilities
  - 10.5.3.3. Financial Details
  - 10.5.3.4. SWOT Analysis
  - 10.5.3.5. Strategic Framework
  - 10.5.3.6. Recent Developments and Future Outlook
- 10.5.4. Dr Reddy's Laboratories
  - 10.5.4.1. Company Details
  - 10.5.4.2. Peptide Synthesis Service Portfolio
  - 10.5.4.3. Peptide Synthesis Facilities
  - 10.5.4.4. Financial Details
  - 10.5.4.5. SWOT Analysis
  - 10.5.4.6. Strategic Framework
  - 10.5.4.7. Recent Developments and Future Outlook
- 10.5.5. Hybio Pharmaceutical
  - 10.5.5.1. Company Details
  - 10.5.5.2. Peptide Synthesis Service Portfolio
  - 10.5.5.3. Peptide Synthesis Facilities
  - 10.5.5.4. SWOT Analysis
  - 10.5.5.5. Strategic Framework
  - 10.5.5.6. Recent Developments and Future Outlook
- 10.5.6. JYMed Peptide
  - 10.5.6.1. Company Details
  - 10.5.6.2. Peptide Synthesis Service Portfolio
  - 10.5.6.3. Peptide Synthesis Facilities
  - 10.5.6.4. SWOT Analysis
  - 10.5.6.5. Strategic Framework
  - 10.5.6.6. Recent Developments and Future Outlook
- 10.5.7. Neuland Labs
  - 10.5.7.1. Company Details
  - 10.5.7.2. Peptide Synthesis Service Portfolio
  - 10.5.7.3. Peptide Synthesis Facilities
  - 10.5.7.4. Financial Details
  - 10.5.7.5. SWOT Analysis
  - 10.5.7.6. Strategic Framework
  - 10.5.7.7. Recent Developments and Future Outlook
- 10.5.8. Sinopep-Allsino Biopharmaceutical
  - 10.5.8.1. Company Details
  - 10.5.8.2. Peptide Synthesis Service Portfolio
  - 10.5.8.3. Peptide Synthesis Facilities
  - 10.5.8.4. Financial Details
  - 10.5.8.5. SWOT Analysis
  - 10.5.8.6. Strategic Framework
  - 10.5.8.7. Recent Developments and Future Outlook
- 10.5.9. SK Pharmteco
  - 10.5.9.1. Company Details
  - 10.5.9.2. Financial Details
  - 10.5.9.3. SWOT Analysis
  - 10.5.9.4. Strategic Framework
  - 10.5.9.5. Recent Developments and Future Outlook
- 10.5.10. WuXi STA (a WuXi AppTec company)
  - 10.5.10.1. Company Details
  - 10.5.10.2. Peptide Synthesis Service Portfolio
  - 10.5.10.3. Peptide Synthesis Facilities
  - 10.5.10.4. Financial Details
  - 10.5.10.5. SWOT Analysis
  - 10.5.10.6. Strategic Framework
  - 10.5.10.7. Recent Developments and Future Outlook

11. RECENT DEVELOPMENTS

11.1. Chapter Overview
11.2. Partnerships and Collaborations
- 11.2.1. Partnerships Models
- 11.2.2. List of Partnerships and Collaborations
- 11.2.3. Analysis by Year of Partnership
- 11.2.4. Analysis by Type of Partnership
- 11.2.5. Analysis by Year and Type of Partnership
- 11.2.6. Analysis by Company Size and Type of Partnership
- 11.2.7. Analysis by Scale of Operation
- 11.2.8. Analysis by Scale of Operation and Type of Partnership
- 11.2.9. Analysis by Green Chemistry Integration
- 11.2.10. Most Active Players: Analysis by Number of Partnerships
- 11.2.11. Analysis by Geography
  - 11.2.11.1. Intercontinental and Intracontinental Agreements
  - 11.2.11.2. Local and International Agreements
11.3. Recent Expansions
- 11.3.1. Expansion Models
- 11.3.2. List of Recent Expansions
- 11.3.3. Analysis by Year of Expansion
- 11.3.4. Analysis by Type of Expansion
- 11.3.5. Analysis by Year and Type of Expansion
- 11.3.6. Analysis by Location of Expanded Facility (Region)
- 11.3.7. Analysis by Location of Expanded Facility (Country)
- 11.3.8. Recent Expansions: Analysis by Location of Expanded Facility and Type of Expansion
- 11.3.9. Most Active Players: Analysis by Number of Expansions
- 11.3.10. Recent Expansions: Analysis by Geography (Country)
11.4. Emerging Peptide Synthesis Technologies
- 11.4.1. Chemo-Enzymatic Peptide Synthesis Technology
- 11.4.2. Continuous Flow Technology
- 11.4.3. Green Chemistry

12. CLINICAL TRIAL ANALYSIS

12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Peptide Therapeutics: Clinical Trials Analysis
- 12.3.1. Analysis by Trial Registration Year
- 12.3.2. Analysis by Number of Patients Enrolled by Trial Registration Year
- 12.3.3. Analysis by Trial Phase
- 12.3.4. Analysis of Trials by Trial Registration Year and Trial Phase
- 12.3.5. Analysis by Number of Patients Enrolled by Trial Phase
- 12.3.6. Analysis by Trial Status
- 12.3.7. Analysis by Trial Registration Year and Trial Status
- 12.3.8. Analysis by Therapeutic Area
- 12.3.9. Analysis by Patient Gender
- 12.3.10. Analysis by Type of Sponsor / Collaborator
- 12.3.11. Analysis by Study Design
  - 12.3.11.1. Analysis by Type of Allocation
  - 12.3.11.2. Analysis by Type of Masking
  - 12.3.11.3. Analysis by Type of Intervention
  - 12.3.11.4. Analysis by Trial Purpose
- 12.3.12. Leading Industry Players: Analysis by Number of Clinical Trials
- 12.3.13. Analysis by Geography
  - 12.3.13.1. Analysis of Clinical Trials by Geography
  - 12.3.13.2. Analysis of Clinical Trials by Geography and Trial Status
  - 12.3.13.3. Analysis of Patients Enrolled by Geography
  - 12.3.13.4. Analysis of Patients Enrolled by Geography and Trial Status

13. REGIONAL CAPABILITY ANALYSIS

13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Overall Landscape of Peptide Synthesis Manufacturing Facilities
13.4. Peptide Synthesis Capability in North America
13.5. Peptide Synthesis Capability in Europe
13.6. Peptide Synthesis Capability in Asia-Pacific and Rest of the World

14. DEMAND ANALYSIS

14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Peptide Synthesis: Annual Global Demand
- 14.3.1. Peptide Synthesis: Annual Clinical Demand
  - 14.3.1.1. Clinical Demand for Peptide Synthesis: Analysis by Phase of Development
- 14.3.2. Peptide Synthesis: Annual Commercial Demand
  - 14.3.2.1. Commercial Demand for Peptide Synthesis: Analysis by Mechanism of Action
- 14.3.3. Peptide Synthesis: Analysis by Type of Peptide Synthesis Method
- 14.3.4. Peptide Synthesis: Analysis by Geographical Regions

15. CAPACITY ANALYSIS

15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Peptide Synthesis: Global Installed Capacity
- 15.3.1. Analysis by Company Size
- 15.3.2. Analysis by Scale of Operation
- 15.3.3. Analysis by Geography
  - 15.3.3.1. Analysis of Peptide Synthesis Capacity in North America
  - 15.3.3.2. Analysis of Peptide Synthesis Capacity in Europe
  - 15.3.3.3. Analysis of Peptide Synthesis Capacity in Asia-Pacific and Rest of the World
- 15.3.4. Analysis by Company Size and Location of Manufacturing Facility
- 15.3.5. Analysis by Chemical Synthesis Method Used
15.4. Concluding Remarks

16. LIKELY PARTNERS ANALYSIS

16.1. Chapter Overview
16.2. Assumptions and Key Parameters
16.3. Scope and Methodology
16.4. Potential Strategic Partners for Peptide Synthesis in North America
16.5. Potential Strategic Partners for Peptide Synthesis in Europe
16.6. Potential Strategic Partners for Peptide Synthesis in Asia Pacific and Rest of the World
16.7. Spider-web Analysis: Potential Strategic Partners

17. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

17.1. Chapter Overview
17.2. Assumptions and Parameter Definitions
17.3. Make versus Buy Decision Making Framework
- 17.3.1. Scenario 1
- 17.3.2. Scenario 2
- 17.3.3. Scenario 3
- 17.3.4. Scenario 4
17.4. Concluding Remarks

18. TOTAL COST OF OWNERSHIP FOR PEPTIDE CONTRACT MANUFACTURING ORGANIZATIONS

18.1. Chapter Overview
18.2. Key Parameters
18.3. Assumptions and Methodology
18.4. Total Cost of Ownership for Peptide Synthesis Organization, Y0-Y20
18.5. Total Cost of Ownership for Peptide Synthesis Organization: Analysis by CAPEX and OPEX, Y0 and Y20
- 18.5.1. Total Cost of Ownership for Peptide Synthesis Organization: Analysis by CAPEX, Y0
- 18.5.2. Total Cost of Ownership for Peptide Synthesis Organization: Analysis by OPEX, Y1-Y20

19. GLOBAL PEPTIDE SYNTHESIS MARKET

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Global Peptide Synthesis Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 19.3.1. Scenario Analysis
  - 19.3.1.1. Conservative Scenario
  - 19.3.1.2. Optimistic Scenario
19.4. Key Market Segmentations

20. PEPTIDE SYNTHESIS MARKET, BY TYPE OF API

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Peptide Synthesis Market: Distribution by Type of API
- 20.3.1. Peptide Synthesis Market for Generic APIs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 20.3.2. Peptide Synthesis Market for New Chemical Entities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
20.4. Data Triangulation and Validation

21. PEPTIDE SYNTHESIS MARKET, BY TYPE OF PEPTIDE SYNTHESIS METHOD

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Peptide Synthesis Market: Distribution by Type of Peptide Synthesis Method
- 21.3.1. Peptide Synthesis Market for Chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 21.3.2. Peptide Synthesis Market for Non-chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
21.4. Data Triangulation and Validation

22. PEPTIDE SYNTHESIS MARKET, BY TYPE OF CHEMICAL SYNTHESIS METHOD

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Peptide Synthesis Market: Distribution by Type of Chemical Synthesis Method
- 22.3.1. Chemical Synthesis Market for Solid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 22.3.2. Chemical Synthesis Market for Liquid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 22.3.3. Chemical Synthesis Market for Hybrid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
22.4. Data Triangulation and Validation

23. PEPTIDE SYNTHESIS MARKET, BY SCALE OF OPERATION

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Peptide Synthesis Market: Distribution by Scale of Operation
- 23.3.1. Peptide Synthesis Market for Commercial Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 23.3.2. Peptide Synthesis Market for Preclinical / Clinical Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
23.4. Data Triangulation and Validation

24. PEPTIDE SYNTHESIS MARKET, BY COMPANY SIZE

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Peptide Synthesis Market: Distribution by Company Size
- 24.3.1. Peptide Synthesis Market for Very Large and Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 24.3.2. Peptide Synthesis Market for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 24.3.3. Peptide Synthesis Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
24.4. Data Triangulation and Validation

25. PEPTIDE SYNTHESIS MARKET, BY GEOGRAPHY

25.1. Chapter Overview
25.2. Assumptions and Methodology
25.3. Peptide Synthesis Market: Distribution by Geography
- 25.3.1. Peptide Synthesis Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.1.1. Peptide Synthesis Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.1.2. Peptide Synthesis Market in Canada, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 25.3.2. Peptide Synthesis Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.1. Peptide Synthesis Market in Belgium, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.2. Peptide Synthesis Market in Switzerland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.3. Peptide Synthesis Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.4. Peptide Synthesis Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.5. Peptide Synthesis Market in Ireland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.6. Peptide Synthesis Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.7. Peptide Synthesis Market in the Netherlands, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.8. Peptide Synthesis Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.9. Peptide Synthesis Market in Sweden, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.2.10. Peptide Synthesis Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 25.3.3. Peptide Synthesis Market in Asia-Pacific and Rest of the World, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.3.1. Peptide Synthesis Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.3.2. Peptide Synthesis Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.3.3. Peptide Synthesis Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.3.4. Peptide Synthesis Market in Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 25.3.3.5. Peptide Synthesis Market in Other Countries, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
25.4. Market Movement Analysis
- 25.4.1. Penetration-Growth (P-G) Matrix
25.5. Data Triangulation and Validation

26. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

26.1. Peptide Synthesis Market in North America: Distribution by Type of API
- 26.1.1. Peptide Synthesis Market in North America for Generic APIs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.1.2. Peptide Synthesis Market in North America for New Chemical Entities, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
26.2. Peptide Synthesis Market in North America: Distribution by Type of Peptide Synthesis Method
- 26.2.1. Peptide Synthesis Market in North America for Chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.2.2. Peptide Synthesis Market in North America for Non-chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
26.3. Peptide Synthesis Market in North America: Distribution by Type of Chemical Synthesis Method
- 26.3.1. Chemical Synthesis Market in North America for Solid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.3.2. Chemical Synthesis Market in North America for Liquid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.3.3. Chemical Synthesis Market in North America for Hybrid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
26.4. Peptide Synthesis Market in North America: Distribution by Scale of Operation
- 26.4.1. Peptide Synthesis Market in North America for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.4.2. Peptide Synthesis Market in North America for Preclinical / Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates
26.5. Peptide Synthesis Market in North America: Distribution by Company Size
- 26.5.1. Peptide Synthesis Market in North America for Very Large and Large Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.5.2. Peptide Synthesis Market in North America for Mid-sized Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.5.3. Peptide Synthesis Market in North America for Small Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27. MARKET OPPORTUNITY ANALYSIS: EUROPE

27.1. Peptide Synthesis Market in Europe: Distribution by Type of API
- 27.1.1. Peptide Synthesis Market in Europe for Generic APIs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.1.2. Peptide Synthesis Market in Europe for New Chemical Entities, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.2. Peptide Synthesis Market in Europe: Distribution by Type of Peptide Synthesis Method
- 27.2.1. Peptide Synthesis Market in Europe for Chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.2.2. Peptide Synthesis Market in Europe for Non-chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.3. Peptide Synthesis Market in Europe: Distribution by Type of Chemical Synthesis Method
- 27.3.1. Chemical Synthesis Market in Europe for Solid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.3.2. Chemical Synthesis Market in Europe for Liquid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.3.3. Chemical Synthesis Market in Europe for Hybrid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
27.4. Peptide Synthesis Market in Europe: Distribution by Scale of Operation
- 27.4.1. Peptide Synthesis Market in Europe for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.4.2. Peptide Synthesis Market in Europe for Preclinical / Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates
27.5. Peptide Synthesis Market in Europe: Distribution by Company Size
- 27.5.1. Peptide Synthesis Market in Europe for Very Large and Large Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.5.2. Peptide Synthesis Market in Europe for Mid-sized Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.5.3. Peptide Synthesis Market in Europe for Small Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC AND REST OF THE WORLD

28.1. Peptide Synthesis Market in Asia-Pacific and Rest of the World: Distribution by Type of API
- 28.1.1. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Generic APIs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.1.2. Peptide Synthesis Market in Asia-Pacific and Rest of the World for New Chemical Entities, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.2. Peptide Synthesis Market in Asia-Pacific and Rest of the World: Distribution by Type of Peptide Synthesis Method
- 28.2.1. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.2.2. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Non-chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.3. Peptide Synthesis Market in Asia-Pacific and Rest of the World: Distribution by Type of Chemical Synthesis Method
- 28.3.1. Chemical Synthesis Market in Asia-Pacific and Rest of the World for Solid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.3.2. Chemical Synthesis Market in Asia-Pacific and Rest of the World for Liquid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.3.3. Chemical Synthesis Market in Asia-Pacific and Rest of the World for Hybrid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.4. Peptide Synthesis Market in Asia-Pacific and Rest of the World: Distribution by Scale of Operation
- 28.4.1. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.4.2. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Preclinical / Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates
28.5. Peptide Synthesis Market in Asia-Pacific and Rest of the World: Distribution by Company Size
- 28.5.1. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Very Large and Large Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.5.2. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Mid-sized Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.5.3. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Small Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
*Detailed information on Chapter 26-28 is available in the Excel Data Packs shared along with the report

29. SWOT ANALYSIS

29.1. Chapter Overview
29.2. Strengths
29.3. Weaknesses
29.4. Opportunities
29.5. Threats
29.6. Comparison of SWOT Factors

30. ROOTS STRATEGIC RECOMMENDATIONS

31. INSIGHTS FROM PRIMARY RESEARCH

32. REPORT CONCLUSION

33. TABULATED DATA

34. LIST OF COMPANIES AND ORGANIZATIONS

35. CUSTOMIZATION OPPORTUNITIES

36. ROOTS SUBSCRIPTION SERVICES

37. AUTHOR DETAILS

簡介目錄圖表

List of Tables

Table 1.1 Peptide Synthesis Market: Report Attributes / Market Segmentations
Table 6.1 Comparison of Major Peptide Synthesizing Processes
Table 6.2 Chromatographic Techniques
Table 7.1 Comparison of Regulatory Landscape of China and India
Table 8.1 Peptide Synthesis Companies: List of Companies
Table 8.2 Peptide Synthesis Companies: Information on Type of API Manufactured and Scale of Operation
Table 8.3 Peptide Synthesis Companies: Information on Type of Service Offered and Peptide Synthesis Method Used
Table 8.4 Peptide Synthesis Companies: Information on Type of Peptide Modification Offered and Type of Purification Technology Used
Table 8.5 Peptide Synthesis Companies: Information on Regulatory Certifications and Accreditations
Table 8.6 List of Custom Peptide Synthesis Companies
Table 10.1 Peptide Synthesis Companies: List of Companies Profiled
Table 10.2 AmbioPharm: Company Overview
Table 10.3 AmbioPharm: Peptide Synthesis Service Portfolio
Table 10.4 AmbioPharm: Peptide Synthesis Facilities and Capabilities
Table 10.5 AmbioPharm: Recent Developments and Future Outlook
Table 10.6 Creative Peptides: Company Overview
Table 10.7 Creative Peptides: Peptide Synthesis Service Portfolio
Table 10.8 Creative Peptides: Peptide Synthesis Facilities and Capabilities
Table 10.9 CSBio: Company Overview
Table 10.10 CSBio: Peptide Synthesis Service Portfolio
Table 10.11 CSBio: Peptide Synthesis Facilities and Capabilities
Table 10.12 CSBio: Recent Developments and Future Outlook
Table 10.13 Bachem: Company Overview
Table 10.14 Bachem: Peptide Synthesis Facilities and Capabilities
Table 10.15 Bachem: Peptide Synthesis Facilities and Capabilities
Table 10.16 Bachem: Recent Developments and Future Outlook
Table 10.17 BCN Peptides: Company Overview
Table 10.18 BCN Peptides: Peptide Synthesis Service Portfolio
Table 10.19 BCN Peptides: Peptide Synthesis Facilities and Capabilities
Table 10.20 BCN Peptides: Recent Developments and Future Outlook
Table 10.21 CordenPharma: Company Overview
Table 10.22 CordenPharma: Peptide Synthesis Service Portfolio
Table 10.23 CordenPharma: Peptide Synthesis Facilities and Capabilities
Table 10.24 CordenPharma: Recent Developments and Future Outlook
Table 10.25 PolyPeptide: Company Overview
Table 10.26 PolyPeptide: Peptide Synthesis Service Portfolio
Table 10.27 PolyPeptide: Peptide Synthesis Facilities and Capabilities
Table 10.28 PolyPeptide: Recent Developments and Future Outlook
Table 10.29 Senn Chemicals: Company Overview
Table 10.30 Senn Chemicals: Peptide Synthesis Service Portfolio
Table 10.31 Senn Chemicals: Peptide Synthesis Facilities and Capabilities
Table 10.32 Auspep: Company Overview
Table 10.33 Auspep: Peptide Synthesis Service Portfolio
Table 10.34 Auspep: Peptide Synthesis Facilities and Capabilities
Table 10.35 Hybio Pharmaceuticals: Company Overview
Table 10.36 Hybio Pharmaceuticals: Peptide Synthesis Service Portfolio
Table 10.37 Hybio Pharmaceuticals: Peptide Synthesis Facilities and Capabilities
Table 10.38 Hybio Pharmaceuticals: Recent Developments and Future Outlook
Table 10.39 Peptide Institute: Company Overview
Table 10.40 Peptide Institute: Peptide Synthesis Service Portfolio
Table 10.41 Peptide Institute: Peptide Synthesis Facilities and Capabilities
Table 10.42 ScinoPharm: Company Overview
Table 10.43 ScinoPharm: Peptide Synthesis Service Portfolio
Table 10.44 ScinoPharm: Peptide Synthesis Facilities and Capabilities
Table 10.45 ScinoPharm: Recent Developments and Future Outlook
Table 11.1 Peptide Synthesis Companies: List of Partnerships and Collaborations, Since 2021
Table 11.2 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Region-wise)
Table 11.3 Peptide Synthesis Companies: List of Recent Expansions, Since 2021
Table 15.1 Peptide Synthesis Companies: Information on Total Installed Capacity (Sample Dataset)
Table 15.2 Peptide Synthesis Companies: Average Capacity based on Company Size (Sample Dataset)
Table 15.3 Peptide Synthesis Capacity: Average Share Based on Synthesis Method (Sample Dataset)
Table 15.4 Global Installed Peptide Synthesis Capacity: Distribution by Company Size (liters)
Table 16.1 Potential Strategic Partners for Peptide Synthesis Companies Based in North America
Table 16.2 Potential Strategic Partners for Peptide Synthesis Companies Based in Europe
Table 16.3 Potential Strategic Partners for Peptide Synthesis Companies Based in Asia-Pacific and Rest of the World
Table 29.1 Peptide Synthesis Companies: Distribution by Year of Establishment
Table 29.2 Peptide Synthesis Companies: Distribution by Year of Experience of Peptide Synthesis Companies
Table 29.3 Peptide Synthesis Companies: Distribution by Company Size
Table 29.4 Peptide Synthesis Companies: Distribution by Location of Headquarters
Table 29.5 Peptide Synthesis Companies: Distribution by Type of Product Manufactured
Table 29.6 Peptide Synthesis Companies: Distribution by Type of API Manufactured
Table 29.7 Peptide Synthesis Companies: Distribution by Scale of Operation
Table 29.8 Peptide Synthesis Companies: Distribution by Type of Service Offered
Table 29.9 Peptide Synthesis Companies: Distribution by Type of Peptide Synthesis Method Used
Table 29.10 Peptide Synthesis Companies: Distribution by Type of Peptide Modification Offered
Table 29.11 Peptide Synthesis Companies: Distribution by Type of Purification Technology Used
Table 29.12 Peptide Synthesis Companies: Distribution by Regulatory Certifications and Accreditations
Table 29.13 Peptide Synthesis Companies: Distribution by Geographical Presence
Table 29.14 Peptide Synthesis Companies: Distribution by Location of Peptide Synthesis Facilities (Region)
Table 29.15 Peptide Synthesis Companies: Distribution by Number of Peptide Synthesis Facilities (Country)
Table 29.16 Bachem: Financial Information, Since 2022 (CHF Million)
Table 29.17 PolyPeptide: Financial Information, Since 2022 (EUR Million)
Table 29.18 ScinoPharm: Financial Information, Since 2022 (NTD Billion)
Table 29.19 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
Table 29.20 Partnerships and Collaborations: Distribution by Type of Partnership
Table 29.21 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 29.22 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Table 29.23 Partnerships and Collaborations: Distribution by Scale of Operation
Table 29.24 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Table 29.25 Partnerships and Collaborations: Distribution by Green Chemistry Integration
Table 29.26 Most Active Players: Distribution by Number of Partnerships
Table 29.27 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 29.28 Partnerships and Collaborations: Local and International Agreements
Table 29.29 Recent Expansions: Cumulative Year-wise Trend, Since 2021
Table 29.30 Recent Expansions: Distribution by Type of Expansion
Table 29.31 Recent Expansions: Distribution by Year and Type of Expansion
Table 29.32 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Table 29.33 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Table 29.34 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion
Table 29.35 Most Active Players: Distribution by Number of Expansions
Table 29.36 Recent Expansions: Distribution by Geography (Country)
Table 29.37 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2021
Table 29.38 Clinical Trial Analysis: Number of Patients Enrolled by Trial Registration Year, Since 2021
Table 29.39 Clinical Trial Analysis: Distribution by Trial Phase
Table 29.40 Clinical Trial Analysis: Distribution of Trials by Trial Registration Year and Trial Phase, Since 2021
Table 29.41 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Phase
Table 29.42 Clinical Trial Analysis: Distribution by Trial Status
Table 29.43 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2021
Table 29.44 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 29.45 Clinical Trial Analysis: Distribution by Patient Gender
Table 29.46 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 29.47 Clinical Trial Analysis: Distribution by Type of Allocation
Table 29.48 Clinical Trial Analysis: Distribution by Type of Masking
Table 29.49 Clinical Trial Analysis: Distribution by Type of Intervention
Table 29.50 Clinical Trial Analysis: Distribution by Trial Purpose
Table 29.51 Leading Industry Players: Distribution by Number of Clinical Trials
Table 29.52 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 29.53 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Table 29.54 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 29.55 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Table 29.56 Regional Distribution of Peptide Synthesis Facilities
Table 29.57 Regional Capability Analysis: Peptide Synthesis Companies in North America
Table 29.58 Regional Capability Analysis: Peptide Synthesis Companies in Europe
Table 29.59 Regional Capability Analysis: Peptide Synthesis Companies in Asia-Pacific and Rest of the World
Table 29.60 Global Demand for Peptide Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Table 29.61 Global Clinical Demand for Peptide Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Table 29.62 Clinical Demand for Peptide Synthesis: Distribution by Phase of Development
Table 29.63 Clinical Demand for Peptide Synthesis: Phase I Trials, Till 2035 (Kilograms)
Table 29.64 Clinical Demand for Peptide Synthesis: Phase II Trials, Till 2035 (Kilograms)
Table 29.65 Clinical Demand for Peptide Synthesis: Phase III Trials, Till 2035 (Kilograms)
Table 29.66 Global Commercial Demand for Peptide Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Table 29.67 Commercial Demand for Peptide Synthesis: Distribution by Mechanism of Action
Table 29.68 Commercial Demand for Peptide Synthesis for GLP-1 Drugs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Table 29.69 Commercial Demand for Peptide Synthesis for non-GLP-1 Drugs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Table 29.70 Global Demand for Peptide Synthesis: Distribution by Type of Peptide Synthesis Method (Kilograms)
Table 29.71 Global Demand for Peptide Synthesis: Distribution by Geographical Regions (Kilograms)
Table 29.72 Global Installed Peptide Synthesis Capacity: Distribution by Company Size
Table 29.73 Global Installed Peptide Synthesis Capacity: Distribution by Range of Installed Capacity (Liters)
Table 29.74 Global Installed Peptide Synthesis Capacity: Distribution by Scale of Operation (Liters)
Table 29.75 Global Installed Peptide Synthesis Capacity: Distribution by Location of Manufacturing Facility (Liters)
Table 29.76 Peptide Synthesis Capacity in North America
Table 29.77 Peptide Synthesis Capacity in Europe
Table 29.78 Peptide Synthesis Capacity in Asia-Pacific and Rest of the World
Table 29.78 Global Installed Peptide Synthesis Capacity: Distribution by Company Size and Location of Manufacturing Facility
Table 29.79 Global Installed Peptide Synthesis Capacity: Distribution by Synthesis Method (Liters)
Table 29.80 Total Cost of Ownership of Peptide Synthesis Organization, Y0-Y20 (USD Million)
Table 29.81 Total Cost of Ownership of Peptide Synthesis Organization: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Table 29.82 Total Cost of Ownership of Peptide Synthesis Organization, Y0: Distribution by CAPEX (USD Million)
Table 29.83 Total Cost of Ownership of Peptide Synthesis Organization, Y1-Y20: Distribution by OPEX (USD Million)
Table 29.84 Global Peptide Synthesis Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.85 Global Peptide Synthesis Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
Table 29.86 Global Peptide Synthesis Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
Table 29.87 Peptide Synthesis Market: Distribution by Type of API
Table 29.88 Peptide Synthesis Market for Generic APIs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.89 Peptide Synthesis Market for New Chemical Entities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.90 Peptide Synthesis Market: Distribution by Type of Peptide Synthesis Method
Table 29.91 Peptide Synthesis Market for Chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.92 Peptide Synthesis Market for Non-chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.93 Peptide Synthesis Market: Distribution by Type of Chemical Synthesis Method
Table 29.94 Peptide Synthesis Market for Solid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.95 Peptide Synthesis Market for Liquid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.96 Peptide Synthesis Market for Hybrid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.97 Peptide Synthesis Market: Distribution by Scale of Operation
Table 29.98 Peptide Synthesis Market for Commercial Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.99 Peptide Synthesis Market for Preclinical / Clinical Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.100 Peptide Synthesis Market: Distribution by Company Size
Table 29.101 Peptide Synthesis Market for Very Large and Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.102 Peptide Synthesis Market for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.103 Peptide Synthesis Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.104 Peptide Synthesis Market: Distribution by Geography
Table 29.105 Peptide Synthesis Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.106 Peptide Synthesis Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.107 Peptide Synthesis Market in Canada, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.108 Peptide Synthesis Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.109 Peptide Synthesis Market in Belgium, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.110 Peptide Synthesis Market in Switzerland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.111 Peptide Synthesis Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.112 Peptide Synthesis Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.113 Peptide Synthesis Market in Ireland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.114 Peptide Synthesis Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.115 Peptide Synthesis Market in the Netherlands, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.116 Peptide Synthesis Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.117 Peptide Synthesis Market in Sweden, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.118 Peptide Synthesis Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.119 Peptide Synthesis Market in Asia-Pacific and Rest of the World, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.120 Peptide Synthesis Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.121 Peptide Synthesis Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.122 Peptide Synthesis Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.123 Peptide Synthesis Market in Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Table 29.124 Peptide Synthesis Market in Other Countries, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Overall Market Landscape
Figure 5.2 Executive Summary: Recent Developments
Figure 5.3 Executive Summary: Clinical Trial Analysis
Figure 5.4 Executive Summary: Demand Analysis
Figure 5.5 Executive Summary: Capacity Analysis
Figure 5.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Methods of Peptide Synthesis
Figure 6.2 Latest Technologies for Peptide Synthesis
Figure 6.3 Peptide Modification Techniques
Figure 6.4 Types of Third-Party Service Providers
Figure 7.1 Regulatory Agencies Governing Peptide Manufacturing in the US
Figure 8.1 Peptide Synthesis Companies: Distribution by Year of Establishment
Figure 8.2 Peptide Synthesis Companies: Distribution by Year of Experience of Companies
Figure 8.3 Peptide Synthesis Companies: Distribution by Company Size
Figure 8.4 Peptide Synthesis Companies: Distribution by Location of Headquarters
Figure 8.5 Peptide Synthesis Companies: Distribution by Type of Product Manufactured
Figure 8.6 Peptide Synthesis Companies: Distribution by Type of API Manufactured
Figure 8.7 Peptide Synthesis Companies: Distribution by Scale of Operation
Figure 8.8 Peptide Synthesis Companies: Distribution by Type of Service Offered
Figure 8.9 Peptide Synthesis Companies: Distribution by Type of Peptide Synthesis Method Used
Figure 8.10 Peptide Synthesis Companies: Distribution by Type of Peptide Modification Offered
Figure 8.11 Peptide Synthesis Companies: Distribution by Type of Purification Technology Used
Figure 8.12 Peptide Synthesis Companies: Distribution by Regulatory Certifications and Accreditations
Figure 8.13 Peptide Synthesis Companies: Distribution by Geographical Presence
Figure 8.14 Peptide Synthesis Companies: Distribution by Location of Peptide Synthesis Facilities (Region)
Figure 8.15 Peptide Synthesis Companies: Distribution by Number of Peptide Synthesis Facilities (Country)
Figure 9.1 Company Competitiveness Analysis: Peptide Synthesis Companies Headquartered in North America
Figure 9.2 Company Competitiveness Analysis: Peptide Synthesis Companies Headquartered in Europe
Figure 9.3 Company Competitiveness Analysis: Peptide Synthesis Companies Headquartered in Asia-Pacific and Rest of the World
Figure 10.1 Bachem: Financial Information, Since 2022 (CHF Million)
Figure 10.2 PolyPeptide: Financial Information, Since 2022 (EUR Million)
Figure 10.3 ScinoPharm: Financial Information, Since 2022 (NTD Billion)
Figure 10.4 Amneal Pharmaceuticals: Company Details
Figure 10.5 Amneal Pharmaceuticals: Financial Details
Figure 10.6 Amneal Pharmaceuticals: SWOT Analysis
Figure 10.7 Amneal Pharmaceuticals: Strategic Framework
Figure 10.8 Amneal Pharmaceuticals: Recent Developments and Future Outlook
Figure 10.9 Asymchem: Company Details
Figure 10.10 Asymchem: Peptide Synthesis Service Portfolio
Figure 10.11 Asymchem: Peptide Synthesis Facilities
Figure 10.12 Asymchem: Financial Details
Figure 10.13 Asymchem: SWOT Analysis
Figure 10.14 Asymchem: Strategic Framework
Figure 10.15 Asymchem: Recent Developments and Future Outlook
Figure 10.16 Aurisco Pharma: Company Details
Figure 10.17 Aurisco Pharma: Peptide Synthesis Facilities
Figure 10.18 Aurisco Pharma: Financial Details
Figure 10.19 Aurisco Pharma: SWOT Analysis
Figure 10.20 Aurisco Pharma: Strategic Framework
Figure 10.21 Aurisco Pharma: Recent Developments and Future Outlook
Figure 10.22 Dr Reddy's Laboratories: Company Details
Figure 10.23 Dr Reddy's Laboratories: Peptide Synthesis Service Portfolio
Figure 10.24 Dr Reddy's Laboratories: Peptide Synthesis Facilities
Figure 10.25 Dr Reddy's Laboratories: Financial Details
Figure 10.26 Dr Reddy's Laboratories: SWOT Analysis
Figure 10.27 Dr Reddy's Laboratories: Strategic Framework
Figure 10.28 Dr Reddy's Laboratories: Recent Developments and Future Outlook
Figure 10.29 Hybio Pharmaceutical: Company Details
Figure 10.30 Hybio Pharmaceutical: Peptide Synthesis Service Portfolio
Figure 10.31 Hybio Pharmaceutical: Peptide Synthesis Facilities
Figure 10.32 Hybio Pharmaceutical: SWOT Analysis
Figure 10.33 Hybio Pharmaceutical: Strategic Framework
Figure 10.34 Hybio Pharmaceutical: Recent Developments and Future Outlook
Figure 10.35 JYMed Peptide: Company Details
Figure 10.36 JYMed Peptide: Peptide Synthesis Service Portfolio
Figure 10.37 JYMed Peptide: Peptide Synthesis Facilities
Figure 10.38 JYMed Peptide: SWOT Analysis
Figure 10.39 JYMed Peptide: Strategic Framework
Figure 10.40 JYMed Peptide: Recent Developments and Future Outlook
Figure 10.41 Neuland Labs: Company Details
Figure 10.42 Neuland Labs: Peptide Synthesis Service Portfolio
Figure 10.43 Neuland Labs: Peptide Synthesis Facilities
Figure 10.44 Neuland Labs: Financial Details
Figure 10.45 Neuland Labs: SWOT Analysis
Figure 10.46 Neuland Labs: Strategic Framework
Figure 10.47 Neuland Labs: Recent Developments and Future Outlook
Figure 10.48 Sinopep-Allsino Biopharmaceutical: Company Details
Figure 10.49 Sinopep-Allsino Biopharmaceutical: Peptide Synthesis Service Portfolio
Figure 10.50 Sinopep-Allsino Biopharmaceutical: Peptide Synthesis Facilities
Figure 10.51 Sinopep-Allsino Biopharmaceutical: Financial Details
Figure 10.52 Sinopep-Allsino Biopharmaceutical: SWOT Analysis
Figure 10.53 Sinopep-Allsino Biopharmaceutical: Strategic Framework
Figure 10.54 Sinopep-Allsino Biopharmaceutical: Recent Developments and Future Outlook
Figure 10.55 SK Pharmteco: Company Details
Figure 10.56 SK Pharmteco: Financial Details
Figure 10.57 SK Pharmteco: SWOT Analysis
Figure 10.58 SK Pharmteco: Strategic Framework
Figure 10.59 SK Pharmteco: Recent Developments and Future Outlook
Figure 10.60 WuXi STA (a WuXi AppTec company): Company Details
Figure 10.61 WuXi STA (a WuXi AppTec company): Peptide Synthesis Service Portfolio
Figure 10.62 WuXi STA (a WuXi AppTec company): Peptide Synthesis Facilities
Figure 10.63 WuXi STA (a WuXi AppTec company): Financial Details
Figure 10.64 WuXi STA (a WuXi AppTec company): SWOT Analysis
Figure 10.65 WuXi STA (a WuXi AppTec company): Strategic Framework
Figure 10.66 WuXi STA (a WuXi AppTec company): Recent Developments and Future Outlook
Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 11.4 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Figure 11.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 11.6 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Figure 11.7 Partnerships and Collaborations: Distribution by Green Chemistry Integration
Figure 11.8 Most Active Players: Distribution by Number of Partnerships
Figure 11.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.10 Partnerships and Collaborations: Local and International Agreements
Figure 11.11 Recent Expansions: Cumulative Year-wise Trend, Since 2021
Figure 11.12 Recent Expansions: Distribution by Type of Expansion
Figure 11.13 Recent Expansions: Distribution by Year and Type of Expansion
Figure 11.14 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Figure 11.15 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Figure 11.16 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion
Figure 11.17 Most Active Players: Distribution by Number of Expansions
Figure 11.18 Recent Expansions: Distribution by Geography (Country)
Figure 11.19 Chemo-Enzymatic Peptide Synthesis Technology: Advantages and Disadvantages
Figure 11.20 Continuous Flow Technology: Advantages and Disadvantages
Figure 11.21 Green Chemistry: Advantages and Disadvantages
Figure 12.1 Clinical Trial Analysis: Scope and Methodology
Figure 12.2 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2021
Figure 12.3 Clinical Trial Analysis: Number of Patients Enrolled by Trial Registration Year, Since 2021
Figure 12.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 12.5 Clinical Trial Analysis: Distribution of Trials by Trial Registration Year and Trial Phase, Since 2021
Figure 12.6 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Phase
Figure 12.7 Clinical Trial Analysis: Distribution by Trial Status
Figure 12.8 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2021
Figure 12.9 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 12.10 Clinical Trial Analysis: Distribution by Patient Gender
Figure 12.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 12.12 Clinical Trial Analysis: Distribution by Type of Allocation
Figure 12.13 Clinical Trial Analysis: Distribution by Type of Masking
Figure 12.14 Clinical Trial Analysis: Distribution by Type of Intervention
Figure 12.15 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 12.16 Leading Industry Players: Distribution by Number of Clinical Trials
Figure 12.17 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 12.18 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Figure 12.19 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 12.20 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Figure 13.1 Regional Distribution of Peptide Synthesis Facilities
Figure 13.2 Regional Capability Analysis: Peptide Synthesis Companies in North America
Figure 13.3 Regional Capability Analysis: Peptide Synthesis Companies in Europe
Figure 13.4 Regional Capability Analysis: Peptide Synthesis Companies in Asia-Pacific and Rest of the World
Figure 14.1 Global Demand for Peptide Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Figure 14.2 Global Clinical Demand for Peptide Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Figure 14.3 Clinical Demand for Peptide Synthesis: Distribution by Phase of Development
Figure 14.4 Clinical Demand for Peptide Synthesis: Phase I Trials, Till 2035 (Kilograms)
Figure 14.5 Clinical Demand for Peptide Synthesis: Phase II Trials, Till 2035 (Kilograms)
Figure 14.6 Clinical Demand for Peptide Synthesis: Phase III Trials, Till 2035 (Kilograms)
Figure 14.7 Global Commercial Demand for Peptide Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Figure 14.8 Commercial Demand for Peptide Synthesis: Distribution by Mechanism of Action
Figure 14.9 Commercial Demand for Peptide Synthesis for GLP-1 Drugs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Figure 14.10 Commercial Demand for Peptide Synthesis for non-GLP-1 Drugs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (Kilograms)
Figure 14.11 Global Demand for Peptide Synthesis: Distribution by Type of Peptide Synthesis Method (Kilograms)
Figure 14.12 Global Demand for Peptide Synthesis: Distribution by Geographical Regions (Kilograms)
Figure 15.1 Global Installed Peptide Synthesis Capacity: Distribution by Company Size
Figure 15.2 Global Installed Peptide Synthesis Capacity: Distribution by Range of Installed Capacity (Liters)
Figure 15.3 Global Installed Peptide Synthesis Capacity: Distribution by Scale of Operation (Liters)
Figure 15.4 Global Installed Peptide Synthesis Capacity: Distribution by Location of Manufacturing Facility (Liters)
Figure 15.5 Peptide Synthesis Capacity in North America
Figure 15.6 Peptide Synthesis Capacity in Europe
Figure 15.7 Peptide Synthesis Capacity in Asia-Pacific and Rest of the World
Figure 15.8 Global Installed Peptide Synthesis Capacity: Distribution by Company Size and Location of Manufacturing Facility
Figure 15.79 Global Installed Peptide Synthesis Capacity: Distribution by Synthesis Method (Liters)
Figure 16.1 Spider-web Analysis: Potential Strategic Partners
Figure 17.1 Make versus Buy Decision Making Framework
Figure 17.2 Make versus Buy Decision Making: Possible Scenario
Figure 18.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 18.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 18.3 Total Cost of Ownership of Peptide Synthesis Organization, Y0-Y20 (USD Million)
Figure 18.4 Total Cost of Ownership of Peptide Synthesis Organization: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Figure 18.5 Total Cost of Ownership of Peptide Synthesis Organization, Y0: Distribution by CAPEX (USD Million)
Figure 18.6 Total Cost of Ownership of Peptide Synthesis Organization, Y1-Y20: Distribution by OPEX (USD Million)
Figure 19.1 Global Peptide Synthesis Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 19.2 Global Peptide Synthesis Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
Figure 19.3 Global Peptide Synthesis Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
Figure 20.1 Peptide Synthesis Market: Distribution by Type of API
Figure 20.2 Peptide Synthesis Market for Generic APIs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 20.3 Peptide Synthesis Market for New Chemical Entities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.1 Peptide Synthesis Market: Distribution by Type of Peptide Synthesis Method
Figure 21.2 Peptide Synthesis Market for Chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.3 Peptide Synthesis Market for Non-chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.1 Peptide Synthesis Market: Distribution by Type of Chemical Synthesis Method
Figure 22.2 Peptide Synthesis Market for Solid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.3 Peptide Synthesis Market for Liquid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.4 Peptide Synthesis Market for Hybrid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.1 Peptide Synthesis Market: Distribution by Scale of Operation
Figure 23.2 Peptide Synthesis Market for Commercial Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.3 Peptide Synthesis Market for Preclinical / Clinical Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.1 Peptide Synthesis Market: Distribution by Company Size
Figure 24.2 Peptide Synthesis Market for Very Large and Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.3 Peptide Synthesis Market for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.4 Peptide Synthesis Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.1 Peptide Synthesis Market: Distribution by Geography
Figure 25.2 Peptide Synthesis Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.3 Peptide Synthesis Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.4 Peptide Synthesis Market in Canada, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.5 Peptide Synthesis Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.6 Peptide Synthesis Market in Belgium, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.7 Peptide Synthesis Market in Switzerland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.8 Peptide Synthesis Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.9 Peptide Synthesis Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.10 Peptide Synthesis Market in Ireland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.11 Peptide Synthesis Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.12 Peptide Synthesis Market in the Netherlands, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.13 Peptide Synthesis Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.14 Peptide Synthesis Market in Sweden, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.15 Peptide Synthesis Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.16 Peptide Synthesis Market in Asia-Pacific and Rest of the World, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.17 Peptide Synthesis Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.18 Peptide Synthesis Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.19 Peptide Synthesis Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.20 Peptide Synthesis Market in Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.21 Peptide Synthesis Market in Other Countries, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.22 Market Movement Analysis: Geography
Figure 25.23 Penetration-Growth (P-G) Matrix: Geography
Figure 26.1 Peptide Synthesis: SWOT Analysis
Figure 26.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 27.1 Concluding Remarks: Overall Market Landscape (I/II)
Figure 27.2 Concluding Remarks: Overall Market Landscape (I/II)
Figure 27.3 Concluding Remarks: Recent Developments (I/II)
Figure 27.4 Concluding Remarks: Recent Developments (I/II)
Figure 27.5 Concluding Remarks: Clinical Trial Analysis
Figure 27.6 Concluding Remarks: Demand Analysis
Figure 27.7 Concluding Remarks: Capacity Analysis
Figure 27.8 Concluding Remarks: Market Sizing and Opportunity Analysis (I/II)
Figure 27.9 Concluding Remarks: Market Sizing and Opportunity Analysis (II/I